Entity family

Browse funders

Organisations named as supporting, sponsoring, or funding research. Examples include Wellcome, NIHR, research councils.

1articles mentioning funders

1funder mentions

1distinct funders extracted

0%of mentions human-reviewed

Active filtersEntity: NCT03610516 ×

NCT03610516

This funder is selected. Its supporting articles are shown below.

NCT036105161

Articles mentioning NCT03610516

1 articles · page 1 of 1

Efficacy, pharmacokinetics and safety of iscalimab (CFZ533) in patients with proliferative lupus nephritis: a randomised, double-blind, placebo-controlled, phase II study

rmdopen · abstract · 2025-08-14 · 1 matching annotations

81.7%

NCT03610516 Iscalimab systemic lupus erythematosus LN CFZ533

…mmunosuppressed and comorbid patients.Trial registration number NCT03610516.…